The report from The Emerging Risk Factors Collaboration1 in this issue of JAMA was designed to determine whether adding apolipoproteins and lipoproteins to routine measurements of total cholesterol and HDL cholesterol (HDL-C) is associated with improved risk prediction for cardiovascular disease (CVD). The additional measurements included apolipoprotein B and A-I, lipoprotein(a), and lipoprotein-associated phospholipase A2. In this large, multicenter study that included 165 544 patients without baseline CVD from 37 prospective cohorts, there were 15 126 new fatal or nonfatal CVD outcomes over a median follow-up of 10.4 years. Overall, replacement of total cholesterol and HDL-C with apolipoproteins or their ratios was not associated with improved CVD risk prediction, whereas adding lipoprotein factors to total cholesterol and HDL-C was associated with slight improvement in CVD risk prediction.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.